Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2021-12-22 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
关于公司控股股东部分股份解除质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the partial release of pledged shares by the controlling shareholder of the company. It details the number of shares released from pledge, the shareholder's total pledged shares, and reassurances about the absence of risks related to the pledged shares. There is no financial statement, management discussion, or detailed report content. The document is short (1564 characters) and serves as a disclosure announcement about share pledge status, which fits the category of Regulatory Filings (RNS) as it is a regulatory disclosure about share pledge changes and does not fit other more specific categories like share issue or director dealings.
2021-12-22 Chinese
关于公司持股5%以上股东股份解除质押的公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement from a company disclosing the release of pledged shares by a shareholder holding more than 5% of the company's shares. It details the number of shares released from pledge, the dates involved, and the shareholder's updated pledge status. This type of disclosure is related to changes in major shareholdings, specifically about share pledges and their release. It is not a financial report, earnings release, or management discussion. It fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels or related share pledge status.
2021-11-02 Chinese
关于公司控股股东部分股份质押的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the pledge of shares by the company's controlling shareholder. It details the number of shares pledged, the proportion of total shares, and the implications for company control and risk. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about share pledging activity by a major shareholder, which fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, not a full report or financial statement.
2021-10-29 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board regarding the review and approval of the company's 2021 third quarter report. It states that the Supervisory Board has reviewed the third quarter report and found it compliant and accurate. However, the document itself does not contain the financial data or the report but refers to the actual third quarter report published separately on the cninfo website (announcement 2021-073). The document length is short (762 characters) and serves as an announcement of the Supervisory Board's approval of the interim report, not the report itself. According to the 'Menu vs Meal' rule, this is an announcement related to an interim/quarterly report, not the report itself. Therefore, the correct classification is Regulatory Filings (RNS), as it is a regulatory announcement about the approval of a report rather than the report itself.
2021-10-26 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from the company 赛隆药业集团股份有限公司 regarding the approval of the 2021 third quarter report. It mentions the board meeting details, attendance, and voting results. The document is short (639 characters) and refers to the actual quarterly report being published separately on a public website (www.cninfo.com.cn) with a different announcement number. This indicates that this document is not the quarterly report itself but an announcement of the board meeting resolution related to the report. Therefore, it fits best under Board/Management Information (MANG) as it concerns board meeting decisions and resolutions.
2021-10-26 Chinese
2021年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "赛隆药业集团股份有限公司 2021 年第三季度报告" which translates to "Sailong Pharmaceutical Group Co., Ltd. 2021 Third Quarter Report." It contains detailed financial data including income statement, balance sheet, cash flow statement, and notes on financial metrics for the third quarter of 2021. The document includes comprehensive financial statements and analysis for a period shorter than a full fiscal year (quarterly). It is not an announcement or a brief summary but a full quarterly report with substantive financial data. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2021
2021-10-26 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.